{"id":"W4391028843","doi":"10.1161/jaha.123.031586","title":"Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial","year":2024,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Brampton Civic Hospital; BC Innovation Council; University of British Columbia; University of Calgary; McGill University Health Centre","funders":"National Health and Medical Research Council; Medical Research Council; National Institutes of Health; Idorsia Pharmaceuticals; Ingham Institute for Applied Medical Research; Astellas Pharma; Sanofi; Kidney Foundation of Canada; Kowa Company; Gilead Sciences; Pfizer; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen; Eli Lilly and Company; AstraZeneca; Novo Nordisk; Verily Life Sciences; Canadian Institutes of Health Research; University of Washington; American Heart Association","keywords":"Canagliflozin; Medicine; Kidney disease; Internal medicine; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Proportional hazards model; Empagliflozin; Placebo; Clinical trial; Endocrinology; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01346785,0.000806751,0.002913946,0.0003622758,0.0003264246,0.00163713,0.0006301218,0.001314843,0.003398432],"category_scores_gemma":[0.01395463,0.0002875548,0.003529605,0.0007713462,0.0006122514,0.0007881105,0.000900932,0.001657449,0.0002910369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000419949,"about_ca_system_score_gemma":0.001125299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008463915,"about_ca_topic_score_gemma":0.001658283,"domain_scores_codex":[0.9912675,0.006330356,0.0004540602,0.0006473816,0.000908022,0.0003927751],"domain_scores_gemma":[0.9937709,0.003298242,0.001170474,0.0007104818,0.0004726731,0.0005771936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7406933,0.003190249,0.0576706,0.006641757,0.05670103,0.0001803554,0.000252468,0.002164783,0.00135176,0.002592272,0.0104486,0.1181128],"study_design_scores_gemma":[0.6297793,0.0469448,0.1972325,0.001949269,0.08929647,0.0003926361,0.0002732121,0.003540821,0.001360777,0.007475169,0.02157363,0.0001813685],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8900819,0.07370186,0.003971618,0.004780333,0.001342058,0.003045357,0.00614923,0.0001309083,0.01679682],"genre_scores_gemma":[0.9804411,0.006156332,0.002299672,0.002142732,0.00168875,0.00196257,0.004060142,0.00002864115,0.001220059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01346785,"threshold_uncertainty_score":0.07122564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00860876618061515,"score_gpt":0.2463434191198825,"score_spread":0.2377346529392673,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}